eagle-i University of PennsylvaniaUniversity of Pennsylvania
See it in Search

CRISPR/Cas9 Mouse Targeting Core

Director: Henao-Mejia, Jorge., MD, PhD

Summary:

The CRISPR/Cas9 Mouse Targeting Core Facility serves to streamline procedures that facilitate investigators' use of the CRISPR/Cas9 genome editing technology for the rapid and economic generation of novel mouse genetic tool. Services offered: KO mice, KI mice - small sequences, CKO mice, KI mice - large sequences.

Affiliations:

People:

Resources:

Services

  • CKO MICE ( Material production service )

    Generation of conditional knock-out (cKO) mice usually requires the design of the targeting strategy, production of Cas9 mRNA and 2 gRNAs, preparation of 2 donor ssDNA templates containing loxp sites, microinjection of one-cell embryos, and screening of founder mice.

  • KI MICE – LARGE SEQUENCES ( Material production service )

    Generation of knock-in (KI) mice containing large sequences (e.g. fluorescent proteins, STOP cassettes) usually requires the design of the targeting strategy, production of Cas9 mRNA and 2 or more gRNA, preparation of donor dsDNA templates, microinjection of one-cell embryos, and screening of founder mice.

  • KI MICE – SMALL SEQUENCES ( Material production service )

    Generation of knock-in (KI) mice containing small sequences (e.g. point mutations, tags) usually requires the design of the targeting strategy, production of Cas9 mRNA and a gRNA, preparation of donor ssDNA templates, microinjection of one-cell embryos, and screening of founder mice.

  • KO mice ( Material production service )

    Generation of knock-out (KO) mice usually requires the design of the targeting strategy, production of Cas9 mRNA and 2 or more gRNAs, microinjection of one-cell embryos, and screening of founder mice. Double, triple or quadruple KO mice of different genes can be accomplished with one injection.


Web Links:

Last updated: 2019-12-13T12:34:24.779-05:00

Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016